Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort

Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed...

Descripción completa

Detalles Bibliográficos
Autores: Segura, Àlex G., Mané Santacana, Anna, Prohens, Llucia, Rodríguez, Natalia, Mezquida, Gisela, Cuesta, Manuel J., Vieta, Eduard, Amoretti, Silvia, Lobo, Antonio, González-Pinto, Ana, Díaz-Caneja, Covadonga M., Roldán Bejarano, Alexandra, Jiménez, Esther, Baeza, Immaculada, Legido, Teresa, Saiz-Ruiz, Jerónimo, Bernardo, Miquel, Mas, Sergi, PEPs Group
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/59714
Acceso en línea:http://hdl.handle.net/10230/59714
http://dx.doi.org/10.1016/j.psychres.2023.115249
Access Level:acceso abierto
Palabra clave:Cannabis
Genetics
Polygenic risk score
Psychosis
Schizophrenia
Descripción
Sumario:Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed to characterize the association between cannabis-related polygenic risk scores (PRS) on cannabis use and clinical course after a FEP. A cohort of 249 FEP individuals were evaluated during 12 months. Symptom severity was measured with the Positive and Negative Severity Scale and cannabis use with the EuropASI scale. Individual PRS for lifetime cannabis initiation (PRSCI) and cannabis use disorder (PRSCUD) were constructed. Current cannabis use was associated with increased positive symptoms. Cannabis initiation at younger ages conditioned the 12-month symptom progression. FEP patients with higher cannabis PRSCUD reported increased baseline cannabis use. PRSCI was associated with the course of negative and general symptomatology over follow-up. Cannabis use and symptom progression after a FEP were modulated by cannabis PRS, suggesting that lifetime initiation and use disorders may have partially independent genetic factors. These exploratory results may be the first step to identify those FEP patients more vulnerable to cannabis use and worse outcomes to ultimately develop tailored treatments.

Similares en LA Referencia